Brief: Ocuphire Pharma Announces Financial Results For Q3 2022

Opus Genetics

04/11/2022 20:32

Nov 4 (Reuters) - Ocuphire Pharma Inc  OCUP.O :
    * OCUPHIRE PHARMA ANNOUNCES FINANCIAL RESULTS FOR THIRD
QUARTER
2022 AND PROVIDES CORPORATE UPDATE
    * TOPLINE DATA FROM ZETA-1 PHASE 2B TRIAL OF ORAL APX3330
EXPECTED
IN EARLY 2023
    * NDA SUBMISSION FOR NYXOL FOR RM AND INITIATION OF VEGA-2
ON
TRACK FOR Q4 2022
    * QTRLY LOSS PER SHARE $0.22
    * Q3 EARNINGS PER SHARE VIEW $-0.29 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX7Y6dnn 
Further company coverage:  OCUP.O 
 ((Reuters.Briefs@thomsonreuters.com;))